We also show that UDCA, an FDA approved drug that is linked to FTD/ALS treatment, stimulates VAPB-PTPIP51 binding and corrects mutant TDP43 induced damage to both the VAPB-PTPIP51 interaction and ER-mitochondria Ca2+ delivery. This evidence concerns the gene VAPB and frontotemporal dementia.